Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -150.70M | -146.09M | -133.81M | -124.29M | -115.88M |
| Total Depreciation and Amortization | 2.35M | 2.32M | 2.29M | 2.19M | 2.09M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.44M | 17.58M | 12.17M | 10.01M | 8.56M |
| Change in Net Operating Assets | 2.13M | 7.89M | 10.33M | 3.19M | 1.65M |
| Cash from Operations | -124.78M | -118.30M | -109.03M | -108.90M | -103.59M |
| Capital Expenditure | -888.00K | -1.06M | -1.31M | -1.20M | -1.14M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -71.10M | 128.61M | -183.34M | -177.40M | -179.40M |
| Cash from Investing | -71.98M | 127.55M | -184.66M | -178.60M | -180.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 196.90M | 10.70M | 249.52M | 299.56M | 296.01M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -214.00K | -300.00K | -262.00K | -213.00K | -213.00K |
| Cash from Financing | 196.68M | 10.40M | 249.25M | 299.35M | 295.80M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -81.00K | 19.66M | -44.43M | 11.85M | 11.68M |